Google AI


Modern Australian

CK Life Sciences Establishes Sequencio Therapeutics to Advance Therapeutic Cancer Vaccines Development

HONG KONG SAR - Media OutReach Newswire - 10 March 2026 - CK Life Sciences Int'l., (Holdings) Inc. ("CK Life Sciences" or the "Company", Stock Code: 0775) today announced the establishment of Sequencio Therapeutics ("Sequencio"), a wholly-owned subsidiary dedicated to advancing the Company's therapeutic cancer vaccine portfolio.



The Third Pillar of a Strategic Reorganisation

This marks the third pillar of a strategic reorganisation, following transactions involving Nasdaq-listed TransCode Therapeutics ("TransCode", "RNAZ") and Dogwood Therapeutics ("Dogwood", "DWTX") completed in 2025 and 2024, respectively. Collectively, these developments are intended to accelerate R&D, enhance operational execution, and broaden capital access for pharmaceuticals and diagnostics R&D, positioning CK Life Sciences at the forefront of therapeutic cancer vaccine development.

Sequencio – A Therapeutic Cancer Vaccine R&DPlatform

Sequencio Therapeutics has been established to consolidate CK Life Sciences' therapeutic cancer vaccine research and development portfolio under a dedicated organisation, reflecting the Company's strategic focus on this emerging class of cancer immunotherapy. The subsidiary is focused on the development of therapeutic cancer vaccines designed to train a patient's own immune system to achieve durable, long-term remission with a favourable safety profile, addressing key limitations of current standard-of-care therapies. The establishment of Sequencio supports a long-term vision of shifting cancer treatment paradigms from transient tumour reduction toward sustained, immune-controlled remission, with vaccine discovery and design conducted in-house and development advanced through a combination of internal capabilities and external collaborations.

Sequencio's preclinical portfolio includes the Company's investigational cancer vaccines targeting Trophoblast Cell Surface Antigen 2 (TROP2), which has demonstrated robust T-cell immune responses and achieved 100% tumour growth inhibition in preclinical breast and colorectal cancer mouse studies. The portfolio also includes vaccine candidates targeting PRAME (Preferentially Expressed Antigen in Melanoma), PD-L1 (programmed cell death ligand 1), B7-H3 (B7 homolog 3), and Claudin 6.

Dr Melvin Toh, Chief Scientific Officer: A Significant Milestone in Ongoing Commitment to Transforming Cancer Treatment

"The establishment of Sequencio marks a significant milestone in our ongoing commitment to transforming cancer treatment," said Dr Melvin Toh, Chief Scientific Officer at CK Life Sciences. "By consolidating our cancer vaccine research under a dedicated entity, we are establishing a focused platform with the agility and expertise required to drive breakthrough science from the laboratory to the clinic, with the aim of delivering potential benefits to patients."

Over the past two years, CK Life Sciences has undergone a comprehensive restructuring to maximise the potential of its R&D portfolio, with a view to attracting additional funding from investors. In 2025, the Company's late-stage melanoma vaccine seviprotimut-L was sold to Nasdaq-listed TransCode in exchange for an equity stake in Transcode. Through the integration of seviprotimut-L into TransCode Therapeutics' pipeline, the potential synergy between vaccine-driven immunity and RNA-based mechanisms presents an opportunity to explore new approaches to addressing treatment resistance and achieving more durable patient responses.

Separately, in 2024, CK Life Sciences completed a transaction with Dogwood Therapeutics, a Nasdaq-listed company focused on developing new medicines for pain and neuropathy, in which CK Life Sciences holds a majority stake. Dogwood is advancing Halneuron® for chemotherapy-induced neuropathic pain, which has demonstrated positive interim Phase 2b results. Dogwood has also secured a global licence to develop an intravenous formulation of SP16 for cancer-related pain.

Both Nasdaq-listed companies are led by experienced scientific and commercial teams, providing greater access to US capital markets and potential strategic partnerships to expedite development. These transactions enable CK Life Sciences' commercial operations to provide initial and standby funding for its in-house preclinical programmes, now consolidated under Sequencio.

With Sequencio, TransCode and Dogwood, CK Life Sciences now offers an R&D platform with a diversified pipeline of early and late-stage projects targeting substantial unmet medical needs.

Mr Alan Yu, Deputy Chairman: Consider Expanding in an Innovative and Hi-tech Zone like the Northern Metropolis

"By leveraging strategic partnerships, access to public markets, and focused internal development, we are combining the agility of dedicated teams, with the resources needed to advance groundbreaking sciences," added Mr Alan Yu, Deputy Chairman of CK Life Sciences. "We look forward to delivering these innovative therapies to the patients who need them most. As our R&D projects mature, we may need to consider expanding our R&D facilities in an innovative and hi-tech zone like that of Hong Kong's Northern Metropolis."


Hashtag: #CKLifeSciences #Sequencio #CancerVaccines #R&D #Pharmaceutical #Dogwood #DWTX #TransCode #RNAZ

The issuer is solely responsible for the content of this announcement.

CK Life Sciences Int'l., (Holdings) Inc.

CK Life Sciences Int'l., (Holdings) Inc. (stock code: 0775) is listed on the Stock Exchange of Hong Kong. With a mission of improving the quality of life, CK Life Sciences is engaged in healthcare research and development, with operating businesses that enable its R&D sustainability. Regarding pharmaceutical research and development, CK Life Sciences' operations are focused on conducting research and development into cancer vaccines, RNA therapeutics and pain management solutions. CK Life Sciences is a member of the CK Hutchison Group. For additional information, please visit .

Pool and Deck Design: How to Plan the Perfect Outdoor Living Space for Your Sydney Home

For many Australians, the backyard is where life happens. Summer barbecues, weekend swims and long evenings outdoors are all part of the lifestyle, ...

Is Solar Pool Heating Worth It? What Sydney Homeowners Should Know

There's nothing quite like a backyard pool on a hot Sydney day. But once autumn rolls in, many pools sit unused for months because the water is simp...

Planning a Luxury House Move: A Week-by-Week Timeline for Prestige Sydney Homes

Selling or buying a prestige home is a major milestone. Whether it's a waterfront residence in Birchgrove, a grand Federation home in Haberfield or ...

Downsizing or Upgrading Your Caravan? Here's How to Sell It Without the Hassle

Selling a caravan can feel like a major task, especially when you are unsure about its value, paperwork, or how to find a buyer. Whether you are dow...

The Best Overseas Adventure Holidays for Australians Who Love the Outdoors

Australia offers no shortage of incredible outdoor experiences, but sometimes the best way to satisfy your sense of adventure is to head overseas. A...

Cape Town Wine Shuttle: Winelands Tasting & Tours

Embark on an unforgettable journey through the picturesque Cape Winelands, where world-class wines and breathtaking scenery await. Our Cape Town Win...

Why Giant Rats Tail Grass Keeps Coming Back After Spraying

Giant Rats Tail Grass (GRT) is one of the most frustrating pasture weeds for farmers and lifestyle property owners. You spray an infested area, see th...

When Custom Cardboard Boxes Make Sense for Your Business

Custom cardboard boxes can be useful when a standard carton does not fit a product, packing method or presentation requirement particularly well. A ...

Bottle Label Printing: Key Factors for a Professional Finish

Why the Printing Method Matters When businesses need packaging or printed containers developed for a particular application, the right supplier can m...

Virtual Livestock Fencing and GPS Tracking: Improving Visibility Across Cattle Properties

What Virtual Livestock Fencing Means for Modern Cattle Management Managing cattle across extensive properties requires more than knowing where anim...

Sydney Pawnbrokers Explained: How Hocking Your Car Actually Works

Sometimes you need cash, and you need it soon. If you own a car, you may already have a way to get it. That's what people mean when they say they've...

Moving Interstate from the Gold Coast to Brisbane (or Back)? What Removalists Wish You Knew First

Have you talked to anyone who’s done the move? They say the same thing: the drive up the M1 is the easy part. It's everything around it that catches...

Why the Spring School Holidays Are a Great Time to Visit Coffs Harbour

The spring school holidays are a good time to spend a few days on the Coffs Coast. The weather is starting to warm up, there is plenty to do outdoor...

What to Do When an Older Car Is No Longer Worth Keeping in Melbourne

Ever looked at another repair quote and wondered whether your old car is still worth the trouble? It is a common turning point for Melbourne motoris...

Your Baby's First Year: A Local Guide to Feeding, Sleep, and When to Get Extra Support

Ask ten parents in a Brisbane mothers' group how their baby is feeding or sleeping, and expect ten different answers.  Someone's baby sleeps throug...

Kitchen and Laundry Makeover Ideas That Don't Require a Full Renovation

Full kitchen renos are expensive — and most people don't actually need one.  They need the kitchen to stop looking like it's stuck in 2009, or they...

How Technology Is Reshaping the Modern Australian Commercial Kitchen

The commercial kitchen has always been shaped by technology. Refrigeration changed how ingredients could be stored, modern ventilation transformed k...

The Number on a Roller Blind Fabric That Nobody Explains

Somewhere in the fabric book, next to the colour name, there is a percentage. Three per cent. Five per cent. Ten per cent. Nobody explains it, most c...